Dr. Daniel Judge and Dr. C. Michael Gibson discuss data presented at ACC 2025: Primary Endpoint Efficacy Results in The Attribute-CM Study: Pre-Specified Sensitivity Analyses Addressed Tafamidis Use. Sponsored by BridgeBio Pharma, Inc